H01AX01 • pegvisomant • Systemic hormonal preparations, excluding sex hormones and insulins | Anterior pituitary lobe hormones and analogues | Other anterior pituitary lobe hormones and analogues
Pegvisomant is a growth hormone receptor antagonist used in the treatment of acromegaly, a condition caused by excessive growth hormone production. It works by blocking the effects of growth hormone on tissues.
The medication is administered subcutaneously, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor growth hormone and IGF-1 levels.
Patients should be aware of potential side effects, such as injection site reactions, fatigue, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, fatigue, and elevated liver enzymes. In rare cases, severe reactions such as hepatotoxicity or allergic reactions may occur. Patients should be informed of these risks before use.
Substance: pegvisomant
Date of last drug list: 01-04-2017
Commercial code: W42028001
Concentration: 15mg
Pharmaceutical form: powder + solvent for injection
Quantity: 30
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).